Project Grant R21AI166523

Award Date 12/1/22
Completion Date 3/31/23
Dollars Obligated $691K
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Tanzania
Similar Awards
This Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), aims to develop tools to facilitate the provision of tuberculosis preventive therapy (TPT) for children and adolescents in primary care settings in low- and middle-income countries. The $212,636 award to Socios En Salud Sucursal Peru, a non-profit healthcare organization in Peru, will fund two key activities:...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,208,700 to the University of California, San Diego (UCSD) to develop a prototype assay for detecting active tuberculosis (TB) disease in people living with HIV. The key products and services to be delivered through this 2-year project include: Determining the analytical performance of the prototype assay by...
This $559,341 Project Grant award from the Fogarty International Center (CFDA 93.989 - International Research and Research Training) will support a research project entitled "Tuberculosis in Malawian Children Under Five Years Old: Exploring Non-Invasive Diagnostic Strategies and the Impact of Malnutrition on Treatment Pharmacokinetics." The primary awardee is the collaborative partnership between Henry Ford Health and Michigan State University Health Sciences. The key products and...
This $201,549 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to better understand the metabolic profiles and outcomes of tuberculosis (TB) patients in Tanzania. The research aims to characterize metabolic factors like obesity and pre-diabetes among TB patients at the time of diagnosis (Aim 1) and track how these metabolic parameters change during the...
This $1,350,312 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 - Allergy and Infectious Diseases Research program supports the development of a rapid, phenotypic drug susceptibility testing (DST) system for tuberculosis (TB). The primary goal is to design and optimize a novel, trehalose-based DST (TRE-DST) that can accurately diagnose TB drug resistance, including for first- and second-line TB drugs. This includes developing and...
This $1,415,374 Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) aims to integrate HIV prevention, including HIV self-testing and pre-exposure prophylaxis (PrEP), into household tuberculosis (TB) contact investigation in Uganda. The key products and services include: 1) Evaluating the implementation, effectiveness, and cost-effectiveness of providing home-based HIV self-testing and PrEP initiation versus...
This federal Project Grant award of $646,561 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports a 5-year study to evaluate the impact of a peer-navigation strategy on tuberculosis (TB) and TB-HIV treatment adherence and clinical outcomes in Uganda. The study aims to implement and assess a multi-component peer-led TB education and adherence counseling strategy, including task-shifting TB counseling to peers with TB,...
This K43 Emerging Global Leader Award from the John E. Fogarty International Center (CFDA 93.989 - International Research and Research Training) provides $109,704 to The Infectious Diseases Institute LIMITED (IDI) in Kampala, Uganda. The goal is to develop and pilot an implementation strategy to integrate tuberculosis (TB) treatment into community pharmacies for people living with both TB and HIV in Uganda. The project aims to: 1) explore barriers and facilitators to integrating TB treatment...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) is funding the development of a novel electrochemical lateral flow assay (ELFA) for the point-of-need diagnosis of active tuberculosis (TB). The $238,500 award will support two specific aims: 1) determining the operating characteristics of the ELFA using contrived samples and bio-banked blood from patients at risk of TB, and 2)...
The $193,316 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research on the relationship between HIV exposure, contact networks, and tuberculosis (TB) in children under 5 years old. The award was made on August 20, 2024 to the Boston Medical Center Corporation, a major academic medical center, and will run through July 31, 2029. A sub-award of this grant was made to...

SERIAL IGRA TESTING OF TANZANIAN ADOLESCENTS TO DETECT TB IN HOUSEHOLD CONTACTS - PROJECT SUMMARY TANZANIA HAS ONE OF THE HIGHEST BURDENS OF TUBERCULOSIS (TB) IN THE WORLD. ACHIEVING GLOBAL TB ELIMINATION UNDER THE 2035 END TB STRATEGY WILL REQUIRE AN EXPANDED FOCUS ON ACTIVE TB CASE FINDING. A KEY COMPONENT OF THE CURRENT CASE FINDING STRATEGY IS TESTING HOUSEHOLD CONTACTS (HCS) OF NEW CASES OF REMOTELY-ACQUIRED BUT RECENTLY DIAGNOSED TB DISEASE (INDEX CASE) TO FIND HCS WHO MAY ALSO HAVE TB DISEASE. ONLY 2-4% OF HOUSEHOLDS ARE TYPICALLY FOUND TO HAVE A PREVIOUSLY UNDETECTED CASE OF TB DISEASE. THIS IS BECAUSE TB DISEASE TYPICALLY REQUIRES 2-5 YEARS TO DEVELOP AFTER EXPOSURE AND INFECTION, SUGGESTING THAT IF TRANSMISSION OCCURRED IN THE HOUSEHOLD THE SOURCE HC MAY HAVE ALREADY BEEN TREATED, RECOVERED OR DIED FROM TB. WE HYPOTHESIZE THAT TESTING HCS OF RECENTLY ACQUIRED (INCIDENT) CASES OF TB INFECTION IS LIKELY TO RESULT IN DETECTION OF A SIGNIFICANTLY HIGHER PROPORTION OF HCS WHO WERE THE SOURCE OF THE ADOLESCENT INFECTION AND STILL HAVE UNDIAGNOSED ACTIVE TB DISEASE. IN A RECENTLY COMPLETED 3-YEAR PROSPECTIVE STUDY IN TANZANIA WE DEVELOPED METHODS FOR SCHOOL-BASED SERIAL TESTING OF ADOLESCENTS TO DETECT NEWLY ACQUIRED TB INFECTION. THE TRIAL USED THE T SPOT INTERFERON GAMMA ASSAY (IGRA) ASSAY TO DETECT NEW INFECTION, AND DETERMINED THAT THE ANNUAL RATE OF NEW INFECTION WAS 2.9%. IN THE PROPOSED 2-YEAR STUDY WE WILL SCREEN 800 ADOLESCENT SCHOOLCHILDREN AND FOLLOW THE ESTIMATED 680 IGRA- NEGATIVE PARTICIPANTS FOR 1.5 YEARS TO DETECT >25 NEW INCIDENT TB INFECTIONS. WE HYPOTHESIZE THAT THE PROPORTION OF THEIR 25 HOUSEHOLDS (AND THEIR 100 HCS) WITH A PREVIOUSLY UNDETECTED CASE OF TB WILL BE AS HIGH AS 14%, AND WILL THEREFORE IDENTIFY A NEW AND MORE ROBUST GLOBAL STRATEGY FOR ACTIVE CASE FINDING. CONTROL HOUSEHOLDS WILL INCLUDE THOSE OF 25 ADOLESCENTS WITH PREVALENT TB INFECTION (100 HCS) AND HOUSEHOLDS OF 25 ADOLESCENTS WITH NO TB INFECTION (100 HCS). THE TRIAL WILL BE CONDUCTED UNDER THE COMPREHENSIVE DARDAR RESEARCH PROGRAM, A 20-YEAR RESEARCH COLLABORATION BETWEEN MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES (MUHAS, TANZANIA) AND THE GEISEL SCHOOL OF MEDICINE AT DARTMOUTH (USA). THIS INNOVATIVE STUDY HAS THE POTENTIAL TO IDENTIFY A GAME-CHANGING STRATEGY FOR MORE EFFECTIVE ACTIVE TB CASE FINDING.

Posted 11/29/22, 12:00 AM